Related Experiment Videos
Coronary bypass graft fate: long-term angiographic study
G M FitzGibbon1, A J Leach, H P Kafka
1Cardio-Pulmonary Unit, National Defence Medical Centre, Ottawa, Ontario, Canada.
Journal of the American College of Cardiology
|April 1, 1991
Summary
Coronary artery bypass graft (CABG) atherosclerosis significantly limits graft usefulness over time, with occlusion rates rising sharply. Early graft health does not predict long-term patency, suggesting a need for novel interventions.
Area of Science:
- Cardiovascular Surgery
- Vascular Biology
- Interventional Cardiology
Background:
- Coronary artery bypass grafting (CABG) is a common treatment for coronary artery disease.
- Long-term graft patency and freedom from atherosclerosis are critical for CABG success.
- Venous grafts are prone to accelerated atherosclerosis, impacting patient outcomes.
Purpose of the Study:
- To evaluate the long-term angiographic progression of atherosclerosis in venous coronary bypass grafts.
- To assess the relationship between early graft appearance and later development of disease and occlusion.
- To determine the impact of graft atherosclerosis on long-term graft utility.
Main Methods:
- Longitudinal angiographic study of 741 venous coronary bypass grafts in 222 patients.
- Grafts were assessed early, at 1 year, 5 years, and late (mean 9.6 years) postoperatively.
- Grafts were graded for patency, presence and extent of atherosclerotic disease, and lesion characteristics.
Main Results:
- Graft occlusion increased from 8% early to 45% by >11.5 years.
- Atherosclerosis developed in grafts, reaching 75% by 10 years postoperatively.
- Early normal graft appearance did not predict later disease; 82% of severely diseased grafts at 5 years were normal at 1 year.
Conclusions:
- Venous coronary bypass graft atherosclerosis severely limits long-term graft utility.
- The unpredictable development of disease and occlusion highlights limitations of current graft surveillance.
- Novel therapeutic strategies, potentially pharmacologic, are needed to combat bypass graft atherosclerosis.